News

Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital, Two River, Venrock,

Specifically, they identified novel dual inhibitors of plasmepsins IX and X (PMIX and PMX), two proteases that are essential to Plasmodium falciparum, the predominant cause of the most

The company will inform the members of the US Congress regarding the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) for the treatment of high-risk individuals with COVID-19.

As part of the collaboration, the AI-driven generative modelling technology of Iktos will be combined with SynFini, a fully automated end-to-end synthetic chemistry system developed by SRI. The

The Series B financing was led by Pivotal bioVenture Partners, with participation from new investors Cormorant Asset Management, Cowen Healthcare Investments, EcoR1 Capital, Fidelity Management & Research Company,

AL101, Ayala’s lead product candidate, is a potent, selective, injectable small molecule gamma secretase inhibitor (GSI) and was granted Orphan Drug Designation in May 2019 for the treatment

Givlaari, an injection for subcutaneous use, is an RNAi therapeutic that targets aminolevulinic acid synthase 1 (ALAS1) to treat AHP, an ultra-rare condition where patients experience severe abdominal

According to the company, Advil Dual Action with Acetaminophen is now the first OTC combination of ibuprofen and acetaminophen to get approval in the US. The new product

Financial considerations Under the terms of the agreement, AstraZeneca has received a payment of $350m from Atnahs. The Company may also receive future sales-contingent payments of up to